Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus QVAR 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus QVAR 40.
ARMONAIR DIGIHALER vs QVAR 40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARMONAIR DIGIHALER contains fluticasone furoate and umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, modulating gene expression to reduce inflammatory mediators. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors, causing bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, leading to smooth muscle relaxation and bronchodilation.
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
2 inhalations (55 mcg each) orally twice daily for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
None Documented
None Documented
Terminal elimination half-life of unchanged arformoterol is approximately 26 hours (range 21-30 hours). This supports twice-daily dosing with approximately 2 days to steady state.
Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30%
Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid